Bell Rock Capital’s Gilead Sciences GILD Stock Holding History

Bell Rock Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-286	Closed	-$20K	–	358
2016 Q4	$20K	Buy	+286	New	+$21.3K	0.02%	243

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Bell Rock Capital's GILD Position: Q1 2017 in Review

Bell Rock Capital sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 286 shares — an estimated $20K sold.

Bell Rock Capital first reported a position in GILD in Q4 2016 and held it in 1 quarter. The position peaked at $20K in Q4 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

Bell Rock Capital reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
Bell Rock Capital sold 286 Gilead Sciences shares in Q1 2017, an estimated $20K.
Bell Rock Capital first reported a position in Gilead Sciences in Q4 2016 and held it in 1 quarter.
Bell Rock Capital's Gilead Sciences position peaked at $20K in Q4 2016.
1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Bell Rock Capital's 13F filing for Q1 2017, filed 5 Dec 2018.